Skip to Content
Merck
All Photos(1)

Documents

Safety Information

1275009

USP

Fluocinolone acetonide

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Fluocinolone acetonide, 6α,9α-Difluoro-11β,16α,17α,21-tetrahydroxy-1,4-pregnadiene-3,20-dione, 6α,9α-Difluoro-16α-hydroxyprednisolone 16,17-acetonide, 6α-Fluorotriamcinolone acetonide, Sinalar, Synandone

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H30F2O6
CAS Number:
67-73-2
Molecular Weight:
452.49
MDL number:
MFCD00010525
UNSPSC Code:
41116107
PubChem Substance ID:
329749865
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

fluocinolone

manufacturer/tradename

USP

mp

267-269 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO

InChI

1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1

InChI key

FEBLZLNTKCEFIT-VSXGLTOVSA-N

Gene Information

human ... NR3C1(2908)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluocinolone acetonide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Fluocinolone Acetonide Cream
  • Fluocinolone Acetonide Ointment
  • Fluocinolone Acetonide Topical Solution
  • Neomycin Sulfate and Fluocinolone Acetonide Cream

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

1275009-100MG:
1275009:
1275009-200MG:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R A Kenley et al.
Pharmaceutical research, 4(4), 342-347 (1987-08-01)
We investigated the degradation of fluocinolone acetonide (FA) incorporated into an oil-in-water cream base. The study examined the influence of temperature (23 to 80 degrees C) and cream pH (pH 2.3 to 6) on FA degradation rates. FA degradation followed
Elizabeth A Sugar et al.
Ophthalmology, 121(10), 1855-1862 (2014-06-09)
To evaluate the 3-year incremental cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for the treatment of noninfectious intermediate, posterior, and panuveitis. Randomized, controlled, clinical trial. Patients with active or recently active intermediate, posterior, or panuveitis enrolled in the Multicenter
Wyatt B Messenger et al.
Drug design, development and therapy, 7, 425-434 (2013-06-06)
Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser photocoagulation was the standard of care for several years, few patients achieved significant improvements in visual acuity. As a result, several pharmacotherapies
Reply: To PMID 24875002.
Trucian A Ostheimer et al.
American journal of ophthalmology, 159(2), 409-410 (2014-12-06)
Lea T Drye et al.
Clinical trials (London, England), 11(6), 635-647 (2014-08-15)
Investigators may elect to extend follow-up of participants enrolled in a randomized clinical trial after the trial comes to its planned end. The additional follow-up may be initiated to learn about longer term effects of treatments, including adverse events, costs
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service